CDEK
← All organizations

Zydus Discovery DMCC

For profitContributed to NME

Also known as: ZYDUS | Zydus Discovery DMCC | ZYDUS HLTHCARE | ZYDUS LIFESCIENCES | Zydus Lifesciences Limited | Zydus lifesciences Limited (Formerly Cadila Healthcare Limited.) | ZYDUS NOVELTECH INC | ZYDUS PHARMS | ZYDUS PHARMS USA | ZYDUS PHARMS USA INC | Zydus Research Centre | Zydus Therapeutics Inc. | ZYDUS WORLDWIDE | Zydus Worldwide DMCC | ZYDUS WORLDWIDE DMCC

Phase 1Phase 2Phase 3Phase 4

Highest phase reached

Phase 4

First clinical trial

Feb 1, 2011

First marketed drug

Mar 2, 1992

First NDA

Feb 26, 2021

Last known activity

Jun 1, 2026

Timeline

1950s

  1. Jun 1, 1952

    Zydus Discovery DMCC— Founded

2010s

  1. Jun 18, 2011

    Nesher Pharms— Acquired

  2. Feb 1, 2017

    Sentynl Theraps Inc— Acquired

  3. Apr 5, 2019

    lacosamide— Marketing Organization

2020s

  1. Feb 26, 2021

    Fosdenopterin— NDA Secondary Org

  2. Feb 26, 2021

    Fosdenopterin— NDA Organization

Drugs by trial phase (17 distinct, 31 trials)

Phase 4 (2 own, 0 via acquisition)

Phase 1 (4 own, 0 via acquisition)

Indications

Studied for

Marketed drugs (322)

Subsidiaries (2 direct, 2 total across the full acquisition tree)

Recent trials (50)

Details

Founded
Pennington, New Jersey, US Jun 1, 1952
First NDA
Feb 26, 2021
Last known activity
Jun 1, 2026

Designations held

  • Orphan drug
  • Priority review
  • Breakthrough therapy